Myeloablative vs non-myeloablative conditioning with allogeneic stem cell transplantation for high risk non-Hodgkin’s lymphoma: Similar outcomes despite differences in disease risk

Non-myeloablative allogeneic peripheral stem cell transplantation for multiple myeloma.

OBJECTIVE To present an institution's 2-year experience of non-myeloablative allogeneic stem cell transplantation among Chinese patients. DESIGN Retrospective study. SETTING Bone marrow transplantation unit at a university hospital, Hong Kong. PATIENTS Ten patients with multiple myeloma who received non-myeloablative allogeneic stem cell transplantation between March 2000 and October 2002...

Allogeneic non-myeloablative stem cell transplantation for the patients with heavily pre-treated refractory lymphoma.

Pemphigus vulgaris treated with allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning.

OBJECTIVES Successful treatment of severe, refractory Pemphigus vulgaris (PV) is reported. METHODS Reduced intensity, non-myeloablative conditioning was employed, followed by allogeneic hematopoietic stem cell transplantation (HSCT) from a fully matched sibling. RESULTS Treatment of refractory PV with myeloablation and subsequent allogenic HSCT has been previously reported, and sustained re...

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations

Allogeneic hematopoietic stem cell transplantation (Allo-HSCT) is a curative treatment option for both malignant and some benign hematological diseases. During the last decade, many of the newer high-dose regimens in different intensity have been developed specifically for patients with hematologic malignancies and solid tumors. Today there are three main approaches used prior to allogeneic tra...

Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia.

BACKGROUND Allogeneic hematopoietic cell transplantation is a potentially curative treatment for patients with acute lymphoblastic leukemia. However, the majority of older adults with acute lymphoblastic leukemia are not candidates for myeloablative conditioning regimens. A non-myeloablative preparative regimen is a reasonable treatment option for this group. We sought to determine the outcome ...